Next Article in Journal
Icariin Ameliorates Cyclophosphamide-Induced Renal Encephalopathy by Modulating the NF-κB and Keap1-Nrf2 Signaling Pathways
Previous Article in Journal
Chitosan Biomaterials: Advances and Challenges—2nd Edition
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 10
10.3390/ijms26104837
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Int. J. Mol. Sci. 2023, 24(9), 7706.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Su et al. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706

by
I-Chang Su
1,2,3,4,†,
Yu-Kai Su
1,2,3,4,†,
Syahru Agung Setiawan
5,6,
Vijesh Kumar Yadav
6,
Iat-Hang Fong
1,2,3,4,
Chi-Tai Yeh
6,7,
Chien-Min Lin
1,2,3,4,* and
Heng-Wei Liu
1,2,3,4,*
1
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan
2
Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan
3
Division of Neurosurgery, Department of Surgery, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan
4
Taipei Neuroscience Institute, Taipei Medical University, Taipei City 11031, Taiwan
5
International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan
6
Department of Medical Research & Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan
7
Continuing Education Program of Food Biotechnology Applications, College of Science and Engineering, National Taitung University, Taitung 95092, Taiwan
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2025, 26(10), 4837; https://doi.org/10.3390/ijms26104837
Submission received: 12 April 2025 / Accepted: 12 May 2025 / Published: 19 May 2025
(This article belongs to the Section Molecular Oncology)
Versions Notes
In the original publication [1], there was a mistake in the Institutional Review Board Statement section of this article. The authors want to add the IRB number and Joint Biobank statement to the Institutional Review Board Statement section of this article. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. The IRB approval number and Joint Biobank statement should be corrected as follows.
Institutional Review Board Statement: The study was approved by the Joint Institutional Review Board (JIRB) of the Taipei Medical University–Shuang Ho Hospital (Approval no.: N202101069, NBCT No.200039, NBCT No.220104, N202101065, N201801070, N202002052 and N202008022). Tissue samples from patients with primary and recurrent GBM were obtained from the Taipei Medical University—Joint Biobank, and complied with the recommendations of the Declaration of Helsinki for Biomedical Research.

Reference

  1. Su, I.-C.; Su, Y.-K.; Setiawan, S.A.; Yadav, V.K.; Fong, I.-H.; Yeh, C.-T.; Lin, C.-M.; Liu, H.-W. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Su, I.-C.; Su, Y.-K.; Setiawan, S.A.; Yadav, V.K.; Fong, I.-H.; Yeh, C.-T.; Lin, C.-M.; Liu, H.-W. Correction: Su et al. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706. Int. J. Mol. Sci. 2025, 26, 4837. https://doi.org/10.3390/ijms26104837

AMA Style

Su I-C, Su Y-K, Setiawan SA, Yadav VK, Fong I-H, Yeh C-T, Lin C-M, Liu H-W. Correction: Su et al. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706. International Journal of Molecular Sciences. 2025; 26(10):4837. https://doi.org/10.3390/ijms26104837

Chicago/Turabian Style

Su, I-Chang, Yu-Kai Su, Syahru Agung Setiawan, Vijesh Kumar Yadav, Iat-Hang Fong, Chi-Tai Yeh, Chien-Min Lin, and Heng-Wei Liu. 2025. "Correction: Su et al. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706" International Journal of Molecular Sciences 26, no. 10: 4837. https://doi.org/10.3390/ijms26104837

APA Style

Su, I.-C., Su, Y.-K., Setiawan, S. A., Yadav, V. K., Fong, I.-H., Yeh, C.-T., Lin, C.-M., & Liu, H.-W. (2025). Correction: Su et al. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Int. J. Mol. Sci. 2023, 24, 7706. International Journal of Molecular Sciences, 26(10), 4837. https://doi.org/10.3390/ijms26104837

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop